Top Ten most popular articles on Pharmafile.com this week
pharmafile | March 2, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the EMA has followed suit with the FDA by announcing changes to the way new drugs will be tested in clinical trials.
In one of the biggest stories that broke towards the end of the year, Allergan finally found out whether its patent deal with a Native American tribe was enough to convince the courts to back off its patents on Restasis.
Check out the week’s ten most popular articles on Pharmafile.com here:
10.UK governmentt report looks to reduce vaccination spending
One of the largest petitions ever to have gone before UK parliament, after it attracted 823,349 signatures, brought about the eventual publication of a report into how vaccines are funded.
9. Takeda to create 70 jobs with €25m Dublin investment
Takeda announced the investment of €25 million to construct a new “modular cell therapy facility dedicated to manufacturing a novel stem cell therapy” at Grange Castle in Dublin and will create up to 70 new jobs in the process.
8. Mylan looks to muscle in on Allergan’s Botox territory
Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner on a Botox biosimilar.
7. Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod
Bavencio finally received some good news following the recommendation from NICE for its use in metastatic Merkel cell carcinoma, with it receiving funding from the Cancer Drug Fund.
6. EMA set to also revise guidelines of Alzheimer’s trials
The EMA, following on from the FDA’s lead earlier this month, announced that it will revise its guidelines on clinical trial studies for the treatment of Alzheimer’s disease from 1 September 2018 onwards.
5. FDA refuses to review Celgene’s ozanimod in multiple sclerosis
Celgene has revealed that the FDA rejected its New Drug Application for ozanimod in the treatment of relapsing forms of multiple sclerosis.
4. Europe approves first therapy for haemophilia A with inhibitors in over 20 years
Roche revealed that Hemlibra was approved by the European Commission for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors.
3. AstraZeneca creates biotech spin-off, $250m in bank
Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely the case for Viela Bio after its creation from AZ.
2. Ipsen: Becoming a “development powerhouse”
Immediately following the release of impressive full year financials, Ipsen CEO David Meek spoke exclusively to Pharmafile.com on how the company is hitting its stride, with an ambitious outlook to grow its product offering in the coming years.
1. Allergan’s patent gamble fails
Allergan’s patent deal with the Saint Regis Mohawk Tribe, an attempt to protect itself from an inter partes review on Restasis, drew a huge number of headlines, mostly condemnatory; the judgement was passed as to whether this manoeuvre was valid and it wasn’t positive for Allergan.
Related Content
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, …
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) …
